Overview

Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial

Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purposes of this are: - To determine the highest doses of Taxol and Navelbine that we can safely give to patients; - To determine what kind of side effects are caused by the combination of Taxol, Navelbine and G-CSF; - To determine whether the combination of Taxol, Navelbine and G-CSF is more effective than standard therapy in treating metastatic breast cancer and prolonging life;
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
Amgen
Bristol-Myers Squibb
GlaxoSmithKline
Treatments:
Paclitaxel
Trastuzumab
Vinorelbine